CAPE TOWN, SA / ACCESSWIRE / May 17, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
M2Bio Sciences is pleased to announce that an approach has been received from an unrelated arms length third party to acquire all the operating subsidiaries of Wuhan General Group (China) for cash.
The operations of Wuhan’s subsidiaries are all in startup mode and loss-making and in need of further financing to continue operations.
If the offer is accepted by Wuhan, the cash will firstly be used to settle the creditors. The majority of credit balances emanate from ongoing legal action against the company, as reported in the formal disclosure statement on OTCIQ.com.
Wuhan expects to make a further press release in the very near future.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / March 30, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Dr. AnnaRx™ is pleased to announce the launch of its new line of CBD Muscle and Joint Rubs endorsed and promoted by MMA Pro Fighter Rob “The Black Tiger” Simbowe.
The initial line will consist of 3 variants:
1. CBD Pain-Relief Extra Strength Muscle Rub – 1200 mg
A deep penetrating, dual-action, medicated broad-spectrum CBD rub that is specially formulated to quickly absorb through the skin and muscle to provide pain relief from muscle and joint-related injuries, strains, and sprains. On contact, it provides deep cooling relief, then activates to heat for deep-penetrating, long-lasting pain alleviation.
2. CBD Warming Pre-Workout Muscle Rub – 600 mg
A medicated broad-spectrum CBD pre-workout muscle rub clinically designed to warm and prepare your muscles before your workout, helps protect against muscle and joint-related injuries, strains, and sprains.
3. CBD Cooling Post-Workout Muscle Rub – 600 mg
A medicated broad-spectrum CBD post-workout muscle rub clinically designed to soothe and cool your muscles post-workout, helps protect against muscle and joint-related injuries, strains, and sprains.
The muscle rubs are a new and exciting addition with strong brand differentiators in the category. They will be available in select major pharmacies and health store chains in South Africa first, then Zambia – Rob’s country of birth and upbringing.
“Having Rob represent the Dr. AnnaRx™ brand is a real honor for us. He has an incredible life story that is so inspiring. His deep knowledge of health, fitness, nutrition, and life skills is remarkable. He’s a true role model for the youth and anyone who aspires to do great things. We are also very excited to serve our consumers with these extraordinary three CBD products. The muscle rubs are made using the highest quality CBD from Colorado, USA, African medicinal ingredients and formulated for maximum results.” – Dr. Anna Morera Leralta – Chief Medical Officer, M2Bio Sciences.
Rob Simbowe, Director of Health and Fitness and Brand Ambassador, M2Bio Sciences added: “The meaning of life is not simply to exist, to survive, but to move ahead, to go up, to achieve, to conquer. The meaning of life differs from man to man, from day to day, and from hour to hour, and that’s why I fight not just in the ring but outside in life too – to be the best version of myself I can possibly be. I use CBD as part of my daily regimen to not let any pain stand in my way – it helps me train harder and be the best version of myself when training and competing.”
ROB SIMBOWE UPCOMING FIGHT:
Simbowe vs Dogodo Date: 09, April 2022 Venue: EFC Performance Institute, Johannesburg, South Africa Find out more here
IMMAF Africa Championships
Rob has recently been selected as part of the coaching staff for the IMMAF Africa Championships, his grass route connection and popularity within the Zambian sporting community allow for the perfect platform launch into the country:
We are proud to have Rob Simbowe on the MMA Zambia board. Rob is a pioneer of the sport here; he is Zambia’s first-ever Pro MMA athlete and EFC fighter. Due to his wealth of experience, he has been selected to be part of the MMA Zambia coaching staff for the IMMAF Africa Championships taking place at the EFC Performance Institute in Johannesburg from the 28th to the 30th of April 2022.
The Dr. AnnaRx™ CBD muscle relief line endorsed by Rob is a fantastic product for athletes and recreational fitness enthusiasts alike. You can be assured that with Rob’s name associated with the brand, like Rob, it does everything it says it does and more. We look forward to our athletes using it as a strong and effective aid for recovery after training and competition,” says Benjamin Bush – MD – Ulemu Fight Academy, President – MMA Zambia.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 28, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Medspresso™ and Liviana™ are delighted to announce that their Premium Coffee and Extra Virgin Olive Oil ranges are now listed in 100+ independent brick and mortar stores in the greater Cape Town, South Africa region.
Since the launch of Medspresso™ and Liviana™ late-2021, the brands have grown significantly in the Western Cape, with the number of stockists increasing weekly. There has also been momentous growth on social media as the stockists share and promote the products on their platforms and websites. Below are a few of the premium stockists carrying our products:
“We launched relatively recently, and there has been an astounding level of interest in both brands. Our partners love the packaging and most of all the actual product – coffees, teas, and olive oils. The sales and marketing team is doing an outstanding job on the road and on social media – we are getting our name out there in a big way and people are noticing us. We are particularly excited about our many new and returning customers.
There is a simple recipe to the brands’ success – quality products and exceptional service to our partners and consumers. We have very specific criteria to be met when selecting new stockists and we are very conscious about choosing partners that share our brands’ values, beliefs, and ethics. Looking forward, we currently have 14 SKUs, and expect to have 42 SKUs on the shelves by the end of 2022.” says Michael Sachar CEO M2Bio Sciences – Food and Beverage.
‘’It was never about getting the products in as many stores as possible. Rather, it was about educating stockists and consumers one by one about the benefits of CBD combined with premium food and beverages. We spent a lot of time refining our supply chain and fine-tuning our efficiencies, which resulted in extremely happy customers. We are poised for expansion across South Africa with Johannesburg being our next city. We have set a goal of 600 stores by year-end.”addedJeff Robinson CEO of M2Bio Sciences.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Publicly traded company (OTC Pink: WUHN) Visit Website Contact via E-mail
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / March 16, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
The event will host approximately 5000 attendees throughout the day and feature investment categories ranging from biotechnology, longevity, regenerative medicine, AI, blockchain, agronomics and many more. The show will also feature the latest insights from well-known personalities in the UK investment industry. Jeff Robinson and Dr. Anna Morera Leralta will meet with retail and institutional investors, academics and speakers Jim Mellon, with whom Dr. Anna Morera Leralta completed an internship in London in 2016 and Dr. Greg Baileyof Juvenescence.
“Both Dr. Anna and I are very excited to attend our fifth Master Investor Show. Expanding our knowledge base and networking is so very important, not to mention being able to attend an event in person finally! We would like to extend an invitation to all our friends in London to join us and meet up for a coffee.” said Jeff Robinson – CEO
Jeff is currently in London (March 16 – March 22) and can be reached at jeff@m2bio.co
Master Investor annually host their flagship event, ‘The Master Investor Show’, introducing private investors to a day filled with networking opportunities, presentations and professional guidance from the leading companies and best experts within the financial and investment sectors. Covering various industries, this event caters to a wide audience and is definitely not one to be missed.
Master Investor Show also provides access to the broadest spectrum of investment opportunities to be found; from Trusts and Funds to Small Cap Companies and beyond to Start-Ups in the early stages of fund raising. Meet and hear from experts about what they are investing in and why.
You can get tickets here or if you can’t make it it can be viewed via livestream here.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / March 10, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
M2Bio Sciences is pleased to announce the rollout of its on-site Ketamine and Supercharged Vitamin IV Therapy at the M2Bio Labs in Hout Bay, Cape Town.
Drip therapy has long been used in hospitals and clinics to administer medicine for the main benefit of 100% bioavailability. This means that all the medicine, nutrients, or minerals are absorbed by the body because it’s being fed directly into the bloodstream.
Supercharged Vitamin and CBD IV Drip
The customized intravenous vitamin drips will offer various therapies and vitamin cocktails designed to target very specific health needs. They will support your physical and mental well-being, detox the body, boost the immune system, assist with recovery from strenuous training sessions, nourish and repair hair, skin, and nails, all to get your mind and body to peak performance.
The drips will offer the following benefits to clients:
Instantly increase the body’s antioxidant, mineral, and nutrient count.
Oxygenate the blood, flush out toxins, help with lymph production.
Increase energy, lower body temperature, decrease constipation.
Reduce swelling and help fight off infections.
Improve sleep quality.
Increased metabolism and potential weight loss.
Aids fertility and libido.
Improve concentration and mental clarity.
There will also be the option of CBD (cannabidiol) vitamin drip as part of the product offering. The IV drip method is the fastest and most effective way to get CBD into the patients’ endocannabinoid system and is far more effective than traditional oral, inhaled, transdermal, or sublingual delivery methods.
Ketamine IV Infusions and Assisted Psychotherapy (KAP)
The labs will also feature a Ketamine Infusion Facility and Ketamine Assisted Psychotherapy for treating patients with mental illness, mood disorders, and chronic pain, these include:
Treatment Resistant Depression
Suicidality
Eating Disorders
Bipolar Disorder
Anxiety and Panic Attacks
PTSD
OCD
Postpartum Depression
Alcoholism and Addiction
Neuralgia
Neuropathic pain associated with Diabetes, Demyelination, Cancer, or HIV.
Complex Regional Pain Syndrome (CRPS).
Pain associated with Multiple Sclerosis or Parkinson’s disease.
Migraine headaches and Fibromyalgia.
Patients will be treated in sessions typically lasting 2-3 hours, this process includes the ketamine administration by fully qualified members of the medical team in a comfortable environment. The medical staff will consist of doctors, nurses, psychologists, and psychiatrists. Patients will be fully guided through the entire process.
“We are very excited about the addition of the IV Vitamin and Ketamine divisions. This will add great depth and value to our current offerings at M2Bio Labs. Our clients and patients will have the opportunity to experience various mental and physical wellness therapies all in one convenient location. We will change many lives for the better at the labs.” said Jeff Robinson, Wuhan General Inc, CEO.
About Ketamine and Ketamine Assisted Psychotherapy
Ketamine is an FDA-approved anesthetic that’s been widely used around the world for more than five decades. It’s also a medication with fast-acting antidepressant properties.
While ketamine isn’t considered a first-line therapy for chronic pain, depression, or any other mental health disorder, it can be used off-label to treat severe cases of depression, anxiety, and PTSD that haven’t responded to conventional medications or therapies.
When ketamine is administered through a slow, constant intravenous (IV) drip, it has calming and therapeutic effects on the regions of your brain that control mood and behavior.
KAP is an integrative psychotherapeutic modality.
By using this therapy during a non-ordinary state of consciousness, the therapist is able to support the patient in their exploration of particular suppressed material with less resistance. The client is encouraged to share as much, or as little as they wish during the administration session. Once the client has fully reconnected with their environment, an integration session is used to explore and make meaning of the material, together with the therapist. There is a strong emphasis on mindfulness, the re-examination of one’s core values, and how to apply value-driven actions into the client’s current life circumstances.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / February 1, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Medspresso™ is pleased to announce the launch of its single-serve Super Booster Functional Mushroom Sachets and Active CBD Sachets.
Medspresso™ has sourced the highest quality raw materials and ingredients for the new lines. The products are ethically sourced, compliant to the highest food standards, and contain zero harmful additives, preservatives or psycho-active THC compounds. The amount of CBD in each product adheres to the legal limit allowed by South African law which amounts to 20 mg per person per day.
Both the CBD and Mushroom products are fully water-soluble and can be added to any hot or cold beverage in a convenient manner, or in the case of the mushroom sachet, enjoyed as a standalone tea. The new products fulfill the ever-growing demand for convenience which has become highly valued by CBD and mushroom health supplement consumers. The products are packaged in easy-to-open, one and two-gram sachets which can be stored and transported with ease.
“We are constantly looking at new and healthy ways to diversify Medspresso™’s portfolio and innovative product offerings for our customers. The introduction of the sachets allow customers a means to enjoy the incredible health benifits of CBD and functional mushrooms with such ease.” – saysMichael Sachar, CEO of M2Bio Sciences Food and Beverage.
The sachets will be sold in retail-ready cartons of twenty sachets per unit. The consumer will have the choice to purchase their monthly supply immediately or buy it from select retailers and resellers in a single sachet format at the point of sale. The flexible nature of the product also sets the stage for various exciting co-branding opportunities with partnered beverage manufacturers, healthcare institutions, retailers as well as hospitality and tourism sectors.
“The new line of CBD and mushroom sachets is a step in the right direction when it comes to offering health and wellness to our ever growing customer base. We believe that the convenience of the single-serve sachets will allow new customers to try and love the product before they invest in larger quantities. The product will be available from our select resellers, online retailers as well as on the Medspresso website.” – says Jeff Robinson, CEO of M2Bio Sciences.
Mushroom Super Booster Sachets – Each sachet contains a mix of 100% natural Lion’s Mane, Turkey Tail, Cordyceps, and Reishi mushroom extract. Mushroom extracts have a much higher concentration of active compounds than the raw mushroom powder used in similar product offerings in the category. The extracts are created through a double extraction process, harnessing remarkably more bioavailability per dose, and in turn, the consumer is rewarded with a superior tasting product that is rapidly absorbed by the digestive system.
Active CBD Sachets – Each Active CBD sachet contains 20 mg of pharmaceutical grade CBD isolate, which is double the amount of similar CBD sachet offerings currently in the South African market. Medspresso prides itself on the quality and traceability of CBD used in all of its products for local and international CBD consumers. Only the purest CBD imported from Colorado, USA with legitimate certificates and licenses are used. The nano-emulsion formula used in the CBD isolate makes the CBD 100% water-soluble and easily absorbed through the gut, allowing the user to experience the full health benefits almost instantaneously. The powder itself is tasteless, odorless, and clear when mixed into the beverage, making for the perfect healthy addition without compromising the taste, color, and experience of the original beverage.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / January 19, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Wuhan General Group, Inc./M2Bio Sciences, Inc. is excited to announce the launch of Neurai Life Sciences.
Neurai Life Sciences is a pre- and clinical-stage biotechnology company focusing on the drug discovery and development of next generation therapies treating mental health disorders. The company will lead the industry in artificial intelligence-driven target discovery, innovative and sustainable small molecule chemistry, and inclusive clinical development in the pursuit of novel therapeutics for major depressive disorder, anxiety disorders, and addiction. Neurai Life Sciences is primed to realize the infinite potential of targeted therapeutics within the brain serotonin receptor-mediated signaling pathways.
With the goal of hiring the best international talent, Neurai Life Sciences has recruited Riyad Domingo Ph.D. as Chief Executive Officer. Dr. Domingo is the current Harvard South Africa Fellow for 2021-2022 and holds a doctorate in Medical Biochemistry with a focus on drug discovery and development from the Institute of Infectious Diseases and Molecular Medicine at the University of Cape Town.
“The consequences of the COVID-19 pandemic have underscored the need for the advancement of neuropsychiatric medicine. Mental illness affects everyone, so we at Neurai believe that our targeted drug development process should consider and include all individuals, independent of age, race, or gender. We leverage emerging technologies including machine learning and novel formulation methods, accompanied by well-established industry approaches, thereby driving the evolution of the mental health industry and how therapeutics are developed in the future. This is absolutely vital for the future of our mental health.” said Dr. Domingo.
Jeff Robinson, Wuhan General Inc, CEO added: “Neurai Life Sciences will pioneer a new field of neuropsychiatric medicine. The company will revolutionize and challenge conventional approaches to developing and treating mental health conditions with new medicines and therapies. With Dr. Domingo at the helm, we know that these new technologies will change the lives of millions globally. Neurai is recruiting the brightest minds in the fields of AI and pharma to further complement the ground-breaking technologies and portfolio of molecular assets that are currently in development under Neurai Life Sciences. Never has there been a greater need to combine technology and medicine to address the global mental illness pandemic.”
At this time, Neurai Life Sciences is a private company and 100% owned by Wuhan General Inc. Neurai Life Sciences will be conducting a capital raise to fund initial preclinical research, development, and validation of select drug candidates.
All Wuhan General Inc. shareholders interested in investing in the capital raise for Neurai Life Sciences or for further information, contact Jeff Robinson, Chief Executive Officer, at jeff@m2bio.co or our web site found here. It is anticipated Neurai Life Sciences will seek a liquidity event for its shareholders at a later date. More details to follow.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / December 31, 2021 /WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
M2Bio Sciences is pleased to announce the rollout of its sustainable packaging solution – Hempcelium™ to be piloted and implemented by it’s Liviana™ Extra Virgin Olive Oil brand. The state-of-the-art sustainable packaging is customized to fit its Extra Virgin Olive Oil glass bottles. The solution is a Hempcelium™ transport packaging foam made from hemp agri-waste and mushroom mycelium.
Hempcelium™ is a unique composite that outperforms most other sustainable alternatives currently available. The Hempcelium™ packaging structure is completely organic and can be grown into almost any shape, making it as versatile as styrofoam or polystyrene, less the damage and pollution that comes from using a conventional synthetic material. Because Hempcelium™ is grown and not produced with chemical compounds that need large amounts of energy to synthesize, the carbon footprint is very low, and there are zero industrial chemical byproducts emitted that are harmful to the natural environment, our water, ecosystems, food-chains and human health.
The unique Hempcelium™ composite has been developed in-house by its team of engineers at the M2Bio Sustainability Labs during 2021 and is ready for the South African market. The company is in the process of obtaining all necessary legal and copyrights pertaining to the trademark name Hempcelium™. M2Bio Sciences’ Intellectual Property and Trademark legal team expects the process to be successfully concluded in Q1 2022.
“When you get the product with the packaging you are able to crumble up the Hempcelium™ foam into your garden bed or soil to decompose and support the health of your vegetation. Hempcelium serves an important function in the decomposition of organic matter in the soil. Research has demonstrated that it acts as a filter, removing groundwater contaminants and pollutants. It has shown potential to remove industrial toxins from the soil, which includes pesticides, chlorine, dioxin (a highly toxic environmental pollutant) as well as PCBs (highly toxic industrial compounds). In the garden, Hempcelium helps to increase nutrients available to plants, improve water efficiency, reduce erosion by acting as a cellular net, and promote root growth by adding oxygen to the soil and releasing nitrogen, phosphate, and other micronutrients. Simply put, it has a ton of benefits.” – Jeff Robinson, CEO of M2Bio Sciences.
Hempcelium™ packaging solution for single & multiple bottles
Mr. Robinson continues: “We and our customers are increasingly aware of the importance of sustainable and biodegradable materials. As a company, it has been at the core of product development to ensure all of our materials and ingredients adhere to such standards. We are now proud to take it to the next level, and deliver our own innovative solution to our customers, by introducing our sustainable packaging foam to one of our brands, Liviana.”
In addition, M2Bio is developing multiple packaging solutions for its other product lines and brands – Medspresso™ and Dr. AnnaRx™, which will be ready during the course of 2022.
“This will be a watershed moment for the sustainability drive globally. M2Bio will licence the technology to the rest of the world, with the goal of reducing and replacing synthetics entirely. We are super stoked for what comes next” – Jeff Robinson, CEO of M2Bio Sciences.
Hempcelium™ packaging solution for Dr. AnnaRx products
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / December 16, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
M2Bio Sciences is pleased to announce its Director of Health and Fitness, Brand Ambassador, and MMA Champion Rob Simbowe (AKA Black Tiger) visited Zambia and hosted the Vulnerable Youth Program and Symposium for underprivileged children. In addition,Rob visited the Fountain of Hope Orphanage, where he grew up, to speak with the kids, offer support, and donate much-needed dry goods in a country that is ravished with poverty, inadequate sanitation, poor health facilities, and widespread diseases like HIV/AIDS. Despite all the economic hardships and obstacles, the orphanage provided Rob with food, shelter, and love when he needed it most.
The first MMA Zambia Symposium took place in Lusaka November 25-28th and was also attended by the current MMA Bellator Featherweight champion, Cris Cyborg Justino.
“The sport of Mixed Martial Arts is a powerful tool for changing lives and for positive social change. We have been blessed to witness firsthand how Cris Cyborg Justino and Rob Simbowe use the sport to uplift those around them and empower young athletes, it’s truly inspiring.” – Ben Bush, MMA Zambia President.
In his role as Director of Health and Fitness, Rob works with the M2Bio Sciences’product development team to create new lines of sports nutrition supplements, topical ointments, muscle rubs, and foodicine product lines designed for athletes and optimum performance. His knowledge of the sports nutrition market and his networkinternationally are invaluable to growing the M2Bio consumer-facing brands – Medspresso™ and Dr. AnnaRx™. Rob Simbowe is also involved in the promotion of the new products as the face of sports nutrition for M2Bio Sciences’ current and new product categories to be launched in 2022.
The Rob Simbowe Story
Born August 14, 1987, Simbowe, an only child, lost his parents in 2000. As an orphan, he lived and slept on the streets of Lusaka, Zambia. During this time he met other street kids who were in the same dire situation and had no place to call home.
“I managed to survive the many cold nights of living with no food, no shelter, and sleeping under bridges to become a professional MMA champion fighter.” – Rob Simbowe.
Simbowe lived on the street until he was taken in by the Fountain of Hope Orphanage located in Lusaka’s Kamwala Township where he was presented with a chance to go to school, which back then, he couldn’t use because he was too used to life on the street.
“Life was hard. I remember what I went through and not having parents, not having anyone support me. I lived at Fountain of Hope in 2001. I was among the first street kids at the orphanage. There were guys who were doing drama. They were not like me because they were patient enough to sit and study, but for me, I couldn’t see that. All I wanted was to work and hustle so I never grabbed the opportunity to study.” – Rob Simbowe.
After realizing that education can make living on the streets a temporary experience instead of a lifelong sentence, Simbowe decided to take up another form of education which was to join the sport of boxing. After relocating to South Africa, Simbowe spent his early years selling sunglasses and African memorabilia to tourists at Cape Town’s beachfront before being spotted by international promoters who helped him become Zambia’s first professional MMA fighter.
“When the opportunity came for me to go to South Africa I just told myself that I will have to give my best and try by all means to survive. I told myself that I’m going to work hard and not take what doesn’t belong to me. I went with strong principles and because of my hard work and good deeds, I’m now reaping good things. If you do good to people, you reap good things.” – Rob Simbowe.
Now being coached by ScorantAya and Sithembiso Hadebeof Untouchable Boxing, Simbowe’s ambition is to become the best fighter he can be and help make a difference in young people’s lives by offering the youth an opportunity and guidance to a healthy path towards a successful life.
Back to His Roots
Coming back to Zambia after so many years of being in South Africa and fighting professional MMA fights, he was compelled to go back to his orphanage, and home of his youth, to encourage the children to study hard, strive to be better, and excel.
“Regardless of who you are, let’s lead a life that will inspire others. Let’s make this world a better place for all of us to live in. It is important to leave a legacy that people can look up to. My journey has been amazing and I have met a lot of people who have helped me. To help me, you don’t need to give me money. To help me you don’t need to give me food. But that piece of advice, that piece of encouragement that can make me a better person.” – Rob Simbowe.
Simbowe’s gesture didn’t go unnoticed as MMA Zambia president Benjamin Bush hailed the athlete for his efforts to make the world a better place by inspiring the vulnerable kids.
“I was moved to tears when Rob was explaining his life story to the girls in the dormitory – I think they must have been between the ages of 6-14, talking to them about tips for life and how to get ahead. It was so moving. It was really something special,” – Ben Bush, MMA Zambia President.
Bush said Simbowe and current Bellator MMA featherweight champion Cris Cyborg Justino played a key role in encouraging Zambian athletes during the first-ever MMA Zambia Symposium.
“The event was a massive success… without Rob, Cyborg, IMMAF and MMASA (Mixed Martial Arts South Africa), and M2Bio Sciences we would be nowhere… we can’t thank them enough. Our mission is all about using the sport for positive social change, creating role models, and creating a platform for athletes to achieve their dreams.” – Ben Bush, MMA Zambia President.
After going through so many challenges as an orphan and former street kid, it is gratifying to see Simbowe excel as an MMA fighter and become an exemplary role model like the greatest UFC champions Israel Adesanya and Kamaru Usman.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
CAPE TOWN, SA / ACCESSWIRE / December 8, 2021 / WUHAN GENERAL GROUP (CHINA), INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
Following the acquisition of 60% of Tsime Pharmaceuticals and Medical Supplies (Pty) Ltd (“Tsime”) in 2020, WGG has now reached an agreement with the remaining shareholders to acquire their shares in exchange for shares in WUHN.
Tsime obtained a license in Lesotho to cultivate, process, and export cannabis for medicinal and scientific purposes and any other legal use.
“A key advantage of the Tsime Lesotho license is that it permits the cultivation, processing, and export of medical cannabis under one single license known as an “Operator’s license”. Other countries require separate licenses for the cultivation, extraction, and sale of final products – it’s a real big win for all stakeholders. By owning 100% of Tsime, we’ve streamlined the group structure in preparation of the construction of the new greenhouses, post-harvest production stations, research facilities, and laboratories.”, commented Jeff Robinson, Wuhan General Group CEO.
“We are equally excited by the Wuhan Group’s other activities. Holding shares in Wuhan allows us to continually benefit from the development of Tsime as one of the Group’s subsidiaries. Mr. Robinson has demonstrated exceptional leadership skills and a remarkable vision for the future, we are very happy to be long term shareholders.”, says Bataung Likate, a Lesotho national and one of the selling shareholders.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
